Allogene Therapeutics Inc
ALLO
NASDAQ
Biotechnology
$2.05
USD
+0.07 (+3.54%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $685.13M
Volume 4.6M
Revenue
$4.64M
TTM
— YoY
Gross Margin
100%
TTM
— YoY
Net Income
$-165.49M
TTM
+30.1%
YoY
Operating Cash Flow
$-102.20M
TTM
+40.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 4.6 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 4.6 |
Selling, General & Administrative | 14.3 | 13.7 | 13.8 | 14.1 | 20.8 |
Other Operating Expenses | 2.4 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 56.8 | 44.9 | 42.4 | 46.1 | 51.6 |
Operating Income | -56.8 | -44.9 | -42.4 | -46.1 | -46.9 |
EBITDA | -51.3 | -41.8 | -39.3 | -43.2 | -44.3 |
Other Income / Expense | -0.0 | -0.1 | 0.2 | 0.2 | -0.1 |
Total Other Income / Expense | 5.9 | 3.5 | 3.6 | 3.5 | 4.2 |
Income Before Income Taxes | -50.9 | -41.4 | -38.8 | -42.6 | -42.7 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -50.9 | -41.4 | -38.8 | -42.6 | -42.7 |
Consolidated Net Income / Loss | -50.9 | -41.4 | -38.8 | -42.6 | -42.7 |
Net Income Attributable to Common Shareholders | -50.9 | -41.4 | -38.8 | -42.6 | -42.7 |
Basic EPS | -$0.23 | -$0.19 | -$0.17 | -$0.18 | -$0.13 |
Diluted EPS | -$0.23 | -$0.19 | -$0.17 | -$0.18 | -$0.13 |
Basic Shares Outstanding | 218.9M | 222.0M | 226.2M | 240.3M | 328.9M |
Diluted Shares Outstanding | 218.9M | 222.0M | 226.2M | 240.3M | 328.9M |